RecallDepth
Class III Terminated

Xiidra (lifitegrast ophthalmic solution), packaged in a) 60 Single-Use Containers: 12 pouches x 5 single-use containers (0.2 mL each vial) (NDC 0078-0911-12) and b) 5- Single-Use Containers (NDC 0078-0911-05) Rx Only, Manufactured by: The Ritedose Corporation, Columbia, SC 29203, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936.

This recall has been terminated (originally issued June 15, 2022).

Company
Novartis Pharmaceuticals Corporation
Recall Initiated
May 10, 2022
Posted
June 15, 2022
Recall Number
D-0982-2022
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
1,187,092 vials
Firm Location
East Hanover, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

Failed Impurities/Degradation Specifications.

Distribution

Nationwide within the United States

Lot / Code Info

Lot #:a) and b) 20E21, 20E22, 20E53, 20E54, 20E95, 20E96, 20ED1, 20ED2, 20ED3, 20EK1 Exp. Date 4/2023; 20F27, 20F28, 20F66, 20F67,20FH6, Exp. Date 05/2023; 20G47, 20G48, 20G49, 20G57, 20GB8, 20GE5, 20GE6, Exp. Date 06/2023; 20M41, 20M42, 20M56, 20M66, 20M67, 20MA4, Exp. Date 07/2023; 20S20, 20S22, 20S44, 20S94, Exp. Date 10/2023; 20SA6, 20SA7, 20SE0, Exp. Date 10/2023, 20TE2, 20TG5, Exp. Date 11/2023.

More recalls by Novartis Pharmaceuticals Corporation

View all recalls by this company →

Other recent Class III Drug recalls